Will Beovu Be A Slow-Burning Blockbuster?
DME Data Boosts Novartis Eye Drug
Expanded indications will be key for Novartis's Beovu and a successful diabetic macular edema trial has provided a fillip, a week after the wet AMD-approved drug posted a 44% slump in sales.
You may also be interested in...
Japan Helps Bayer’s Eylea Sales To Sparkle
Eye disease drugs have struggled to grow during the pandemic but Bayer's Regeneron-partnered blockbuster is going from strength to strength, helped by growth in Japan.
Novartis Big Earners Beat Q1 Forecasts
Cosentyx defied the odds again by growing strongly despite US formulary changes, COVID-19 and fierce competition, while the jump in Entresto sales helped soften the drug's failure in a closely watched myocardial infarction study.
Roche Prepares Faricimab For Filing After Phase III AMD Data
Top-line Phase III data for faricimab in age-related macular degeneration leave Roche poised to file the bi-specific antibody for retinal diseases, but again there is no advantage with the novel dual-acting product over Eylea.